Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin

Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin

Saved in:

Bibliographic Details
Main Authors:	Yu-Hsiang Lin, Kuo-Hsuan Chang, Yu-Jen Lu
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Pharmacological Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661825000350
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care
by: Agnieszka Parfianowicz, et al.
Published: (2025-02-01)

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs
by: Nikolaos Theodorakis, et al.
Published: (2025-01-01)

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024-01-01)

The interplay of aging, sleep dysregulation, and mitochondrial dysfunction in metabolic and neurodegenerative diseases
by: Kuo-Jen Lin, et al.
Published: (2025-02-01)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
by: Luis D'Marco, et al.
Published: (2021-01-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus
by: Thiquynhnga Nguyen, et al.
Published: (2020-01-01)

Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists
by: Mayeesha Ahmed, et al.
Published: (2025-02-01)

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
by: Chloé Amouyal, et al.
Published: (2016-01-01)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
by: Wenjun Sha, et al.
Published: (2020-01-01)

Optimización SGLT2 para cardionefro protección
by: Yukiko Harumi Yamasaki Ramos, et al.
Published: (2025-01-01)

Therapies for Mitochondrial Disorders
by: Kayli Sousa Smyth, et al.
Published: (2022-12-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
by: Chen-Ning Wu, et al.
Published: (2020-01-01)

Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial Infarction
by: Elizabeth J. Wright, et al.
Published: (2016-01-01)

Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis
by: Shu Meguro, et al.
Published: (2014-01-01)

Assessment of Antidiabetic Potential and Phytochemical Profiling of Viscum album, a Traditional Antidiabetic Plant
by: Manzoor Ullah, et al.
Published: (2022-01-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

Interleukin-4 Promotes Myogenesis and Boosts Myocyte Insulin Efficacy
by: Yih-Hsin Chang, et al.
Published: (2019-01-01)

Pharmacogenetics of Oral Antidiabetic Drugs
by: Matthijs L. Becker, et al.
Published: (2013-01-01)

Rapid Acting Insulin Use and Persistence among Elderly Type 2 Diabetes Patients Adding RAI to Oral Antidiabetes Drug Regimens
by: Usha Sambamoorthi, et al.
Published: (2016-01-01)

Differential Processing of Cytosolic and Mitochondrial Caspases
by: Hua Yuan, et al.
Published: (2001-01-01)

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)

Cobalt Protoporphyrin Downregulates Hyperglycemia-Induced Inflammation and Enhances Mitochondrial Respiration in Retinal Pigment Epithelial Cells
by: Peng-Hsiang Fang, et al.
Published: (2025-01-01)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
by: Qasim Zafar Iqbal, et al.
Published: (2020-01-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Evaluation on Antidiabetic Properties of Medicinal Plants from Myanmar
by: Dongdong Zhang, et al.
Published: (2021-01-01)

Insulin Therapy in Diabetic Hyperglycemic Emergencies
by: Diana Machado Ramírez, et al.
Published: (2014-09-01)

The Improvement of Hyperglycemia after RYGB Surgery in Diabetic Rats Is Related to Elevated Hypothalamus GLP-1 Receptor Expression
by: Jazyra Zynat, et al.
Published: (2016-01-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

Novel soybean peptide iglycin ameliorates insulin resistance of high-fat diet fed C57BL/6J mice and differentiated 3T3L1 adipocytes with improvement of insulin signaling and mitochondrial function
by: Yinghuan Wu, et al.
Published: (2022-11-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Bioinformatics insights into mitochondrial and immune gene regulation in Alzheimer's disease
by: Tian Meng, et al.
Published: (2025-02-01)

A Survey of Insulin-Dependent Diabetes—Part I: Therapies and Devices
by: Daisuke Takahashi, et al.
Published: (2008-01-01)

A Survey of Insulin-Dependent Diabetes—Part I: Therapies and Devices
by: Daisuke Takahashi, et al.
Published: (2008-01-01)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
by: Ranin Saad, et al.
Published: (2022-01-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)